

(19)



(11)

EP 2 703 814 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(43) Date of publication:

05.03.2014 Bulletin 2014/10

(51) Int Cl.:

G01N 33/53 (2006.01) **C12N 9/64** (2006.01)
C12N 15/09 (2006.01)

(21) Application number: **12776929.7**

(86) International application number:

PCT/JP2012/061097

(22) Date of filing: **25.04.2012**

(87) International publication number:

WO 2012/147798 (01.11.2012 Gazette 2012/44)

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(72) Inventors:

- **OBARA, Takashi**
Tsukuba-shi
Ibaraki 300-2635 (JP)
- **INOUE, Eiji**
Kobe-shi
Hyogo 650-0047 (JP)

(30) Priority: **25.04.2011 JP 2011097377**

(71) Applicant: **Eisai R&D Management Co., Ltd.**
Tokyo 112-8088 (JP)

(74) Representative: **HOFFMANN EITLE**

Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) **METHOD FOR DETECTING NEUROLOGICAL DISEASE ASSOCIATED WITH COGNITIVE DYSFUNCTION BY MEASURING EPHA4 EXTRACELLULAR DOMAIN**

(57) A method for detecting a neurological disease associated with cognitive impairment, wherein the extracellular domain of EphA4 is measured from a biological sample taken from a subject.

EP 2 703 814 A1

Description

TECHNICAL FIELD

5 **[0001]** The present invention relates to a method for detecting or diagnosing a neurological disease associated with cognitive impairment by measuring the extracellular domain of EphA4, and a detection or diagnostic kit for this purpose.

BACKGROUND ART

10 **[0002]** Eph receptor A4 (EphA4) is a member of the receptor tyrosine kinase family and is a molecule regulating postsynaptic morphogenesis. It is known that knockout of EphA4 or expression of an EphA4 dominant-negative mutant causes a reduction in the number of spines, which are small thorn-like protrusions found on dendrites, and also makes their shape slender (Non-patent Document 1). It is generally proposed that the processes of memory and learning are reflected in the number and/or morphology of spines.

15 **[0003]** Recent studies have clarified that this EphA4 undergoes γ -secretase-mediated cleavage and the cleaved intracellular fragment activates a small GTP-binding protein, Rac, to thereby stimulate spine formation (Patent Documents 1 and 2, and Non-patent Document 2). During the above γ -secretase-mediated cleavage process, full-length EphA4 is first cleaved by another type of protease (MMP (matrix metalloproteinase) family) different from γ -secretase to separate the extracellular domain of EphA4. The region remaining on the cell membrane after MMP-mediated cleavage is then
20 cleaved by γ -secretase. Moreover, it is known that MMP-mediated cleavage of the EphA4 extracellular domain is induced in a neuronal activity-dependent manner (Non-patent Document 2), and it is also known that this cleavage reaction of the extracellular domain is a rate-limiting step in this series of cleavage processes.

[0004] However, it has not been clarified for what type of disease EphA4 or its extracellular domain serves as a marker.

25 Prior Art Documents

Patent Documents

[0005]

30 Patent Document 1: WO2008/150010
Patent Document 2: WO2009/069808

Non-patent Documents

35 **[0006]**

Non-patent Document 1: Murai KK, Nguyen LN, Irie F, Yamaguchi Y, Pasquale EB. Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. *Nat Neurosci.* 2003 Feb; 6(2): 153-60.
40 Non-patent Document 2: Inoue E, Deguchi-Tawarada M, Togawa A, Matsui C, Arita K, Katahira-Tayama S, Sato T, Yamauchi E, Oda Y, Takai Y. Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation. *J Cell Biol.* 2009 May 4; 185(3): 551-64.

SUMMARY OF THE INVENTION

45 PROBLEM TO BE SOLVED BY THE INVENTION

[0007] The object of the present invention is to provide a method for detecting or diagnosing a neurological disease associated with cognitive impairment by using the extracellular domain of EphA4 as an indicator, and a kit for use in this
50 detection or diagnosis.

MEANS TO SOLVE THE PROBLEM

[0008] As a result of extensive and intensive efforts made to achieve the above object, the inventors of the present
55 invention have found that EphA4 is reduced in patients with neurological diseases associated with cognitive impairment, e.g., Alzheimer's disease patients or mild cognitive impairment (MCI) patients before developing Alzheimer's disease. Based on this finding, the inventors of the present invention have further found that a neurological disease associated with cognitive impairment can be detected when using the extracellular domain of EphA4 as an indicator. These findings

led to the completion of the present invention.

[0009] Namely, the present invention is as follows.

5 (1) A biomarker for a neurological disease associated with cognitive impairment, which comprises the extracellular domain of EphA4.

(2) The marker according to (1) above, wherein said EphA4 is a protein shown in (a) or (b) below:

(a) a protein which consists of the amino acid sequence shown in SEQ ID NO: 1 or 2; or

10 (b) a protein which consists of an amino acid sequence with deletion, substitution or addition of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 1 or 2 and which serves as a substrate for matrix metalloproteinase or γ -secretase.

(3) A method for detecting a neurological disease associated with cognitive impairment, which comprises the following steps:

15 (a) contacting a biological sample taken from a subject with an antibody which binds to the extracellular domain of EphA4 to thereby measure the amount of the EphA4 extracellular domain; and

(b) determining the subject as suffering from or being at risk of suffering from a neurological disease associated with cognitive impairment if the amount of the EphA4 extracellular domain derived from the subject is lower than a control.

(4) A method for diagnosing a neurological disease associated with cognitive impairment, which comprises the following steps:

25 (a) contacting a biological sample taken from a subject with an antibody which binds to the extracellular domain of EphA4 to thereby measure the amount of the EphA4 extracellular domain; and

(b) diagnosing the subject as suffering from or being at risk of suffering from a neurological disease associated with cognitive impairment if the amount of the EphA4 extracellular domain derived from the subject is lower than a control.

30 (5) The method according to (3) or (4) above, wherein the biological sample is a body fluid.

(6) The method according to (5) above, wherein the body fluid is at least one selected from the group consisting of blood, serum, plasma, blood cells, urine, spinal fluid, saliva, lacrimal fluid and sweat

(7) The method according to any one of (3) to (6) above, wherein the amount of the EphA4 extracellular domain is measured by ELISA.

(8) The method according to any one of (3) to (7) above, wherein the neurological disease associated with cognitive impairment is a disease with reduced neuronal activity in glutamatergic neurons.

(9) The method according to any one of (3) to (8) above, wherein the neurological disease associated with cognitive impairment is Alzheimer's disease, mild cognitive impairment or frontotemporal dementia.

40 (10) A kit for detecting or diagnosing a neurological disease associated with cognitive impairment, which comprises an antibody which binds to the extracellular domain of EphA4.

EFFECTS OF THE INVENTION

45 **[0010]** The present invention enables the detection of neurological diseases associated with cognitive impairment, such as Alzheimer's disease and mild cognitive impairment (MCI), by using a reduction in the extracellular domain of EphA4 as an indicator.

[0011] The present invention will be described in more detail below.

50 BRIEF DESCRIPTION OF THE DRAWINGS

[0012]

Figure 1 schematically shows the cleavage process (processing pathway) of EphA4.

55 Figure 2 shows a distribution of the measured values obtained by ELISA for the concentration of EphA4 extracellular domain in plasma analytes.

DESCRIPTION OF EMBODIMENTS

5 [0013] The present invention will be described in more detail below. The following embodiments are illustrated to describe the present invention, and it is not intended to limit the present invention only to these embodiments. The present invention can be implemented in various modes, without departing from the spirit of the present invention.

[0014] It should be noted that all publications cited herein, including prior art documents, patent gazettes and other patent documents, are incorporated herein by reference. Moreover, this specification incorporates the contents disclosed in the specification of Japanese Patent Application No. 2011-097377 (filed on April 25, 2011), based on which the present application claims priority.

10 [0015] The present invention is directed to a method in which the extracellular domain of EphA4 is used as an indicator (biomarker) for detection or diagnosis of neurological diseases associated with cognitive impairment. This method has now been completed based on the finding that the extracellular domain of EphA4 is reduced in patients with neurological diseases associated with cognitive impairment (e.g., Alzheimer's disease, mild cognitive impairment or frontotemporal dementia) when compared to normal subjects.

15 [0016] As used herein, the term "EphA4" refers to a known polypeptide serving as a regulatory factor for synapse formation and/or maintenance (Murai KK et al., Nat Neurosci. 2003 Feb; 6(2):153-60). EphA4 is structured to comprise an MMP cleavage site, a γ -secretase cleavage site, a transmembrane domain and a kinase active site, and its ligand is among the Ephrin A family (Aoto, J et al., Brain Res. 2006 11).

20 [0017] As used herein, the term "extracellular domain" refers to an N-terminal fragment of EphA4, which will be released into the extracellular environment upon MMP-mediated cleavage. The extracellular domain of EphA4 is also referred herein as the "EphA4 extracellular domain."

25 [0018] As used herein, the term "fragment of the intracellular region" refers to a cleavage product of EphA4 after MMP-mediated cleavage, i.e., a C-terminal fragment of EphA4 which is not the extracellular domain. Such a fragment of the intracellular region includes a transmembrane domain and an intracellular domain, and it serves as a substrate for γ -secretase. A subfragment released into cells from the fragment of the intracellular region upon γ -secretase-mediated cleavage is referred to as an EphA4 intracellular domain (EICD).

[0019] The cleavage process (processing pathway) of EphA4 is schematically shown in Figure 1.

30 [0020] As shown in Figure 1, once neuronal activity has occurred and neurotransmitters have acted on the NMDA receptor (NMDAR), which is a glutamate receptor, MMP (matrix metalloproteinase)-mediated EphA4 cleavage reaction will be induced to cleave EphA4 into a fragment of the extracellular region released into the extracellular environment (i.e., the extracellular domain) and a fragment of the intracellular region remaining within the membrane and cell (i.e., a fragment including the transmembrane domain and the intracellular domain). After MMP-mediated cleavage, the fragment of the intracellular region will further be cleaved by γ -secretase and released as an intracellular domain (i.e., EICD) (released into the cell).

35 [0021] In subjects without cognitive impairment, including normal subjects, EphA4 cleavage reaction will proceed by the action of MMP and γ -secretase, so that the extracellular domain and EICD will be cleaved and released from EphA4. On the other hand, in patients with neurological diseases associated with cognitive impairment, the extracellular domain is less likely to be cleaved and released or is not cleaved and released due to their reduced neurological functions. Since the MMP-cleaved EphA4 extracellular domain is released into the extracellular environment, it is possible to detect or diagnose a neurological disease associated with cognitive impairment when the amount of this domain is measured in a subject.

40 [0022] Namely, the presence of the EphA4 extracellular domain is indicative of the absence of cognitive impairment, while the absence of the EphA4 extracellular domain or its reduction in comparison with a control is indicative of the presence of a neurological disease associated with cognitive impairment. The inventors of the present invention have found, ahead of others, that a neurological disease associated with cognitive impairment can be detected or diagnosed when the amount of the EphA4 extracellular domain is measured using a specific antibody which binds to the EphA4 extracellular domain. Namely, the inventors of the present invention have demonstrated that the EphA4 extracellular domain in a subject serves as a biological indicator for neurological diseases associated with cognitive impairment and can be used as a biomarker. Based on this finding, the inventors have demonstrated that the amount of the EphA4 extracellular domain in a subject can serve as a biological indicator for neurological diseases associated with cognitive impairment. Thus, the present invention enables the determination of whether or not a subject has a neurological disease associated with cognitive impairment by measuring the amount of the EphA4 extracellular domain derived from the subject. The present invention provides a method for detecting or diagnosing a neurological disease associated with cognitive impairment using the extracellular domain of EphA4, which comprises the step of measuring the amount of the EphA4 extracellular domain from a biological sample taken from a subject. This detection step may be accomplished as shown in (a) and (b) below, by way of example:

(a) contacting a biological sample derived from a subject with an antibody which binds to the EphA4 extracellular

domain to thereby measure the amount of the EphA4 extracellular domain; and

(b) allowing the amount of the EphA4 extracellular domain to be correlated with a neurological disease associated with cognitive impairment.

5 **[0023]** The result thus obtained is used as a biological indicator for determining whether the subject suffers from or is at a high risk of suffering from a neurological disease associated with cognitive impairment. In the detection and diagnosis methods of the present invention, the amount of the EphA4 extracellular domain is correlated with a neurological disease associated with cognitive impairment on the basis of the following criteria.

10 **[0024]** If the amount of the EphA4 extracellular domain derived from a subject is lower than a control (e.g., the amount of the EphA4 extracellular domain derived from normal subjects and/or Parkinson's disease patients), the subject is determined or diagnosed as suffering from or being at a high risk of suffering from a neurological disease associated with cognitive impairment. The control may include the amount of the EphA4 extracellular domain derived from patients with various neurological diseases as long as they are free from cognitive impairment, but it is preferably the amount of the EphA4 extracellular domain derived from normal subjects and/or Parkinson's disease patients, and more preferably the amount of the EphA4 extracellular domain derived from normal subjects. It should be noted that cases where the amount of the EphA4 extracellular domain derived from a subject is lower than the control also include those where the amount of the EphA4 extracellular domain derived from a subject is below the detection limit.

15 **[0025]** As used herein, the term "amount" refers to the absolute or relative amount of EphA4 in a sample, which can be expressed as a concentration or may be simply expressed as whether or not EphA4 is present, i.e., expressed as the presence or absence of EphA4. The term "contact" is intended to mean that the EphA4 extracellular domain and an antibody which binds to the EphA4 extracellular domain are placed in an environment where they can be reacted with each other under given conditions, as exemplified by mixing of the above antibody into a sample containing the EphA4 extracellular domain, adding the above sample to a reaction system containing the antibody, etc.

20 **[0026]** When the EphA4 extracellular domain is contacted with the antibody which binds to the EphA4 extracellular domain, the anti-EphA4 extracellular domain antibody will bind to the EphA4 extracellular domain via antigen-antibody reaction. In the case of a reaction system using a biological sample derived from a normal subject or a biological sample derived from a patient without cognitive impairment (e.g., a patient with Parkinson's disease), cleavage reaction occurs on EphA4 to thereby cleave and release the EphA4 extracellular domain. In contrast, in a reaction system using a biological sample derived from a patient with a neurological disease associated with cognitive impairment, little or no cleavage reaction occurs on EphA4, so that the amount of the EphA4 extracellular domain is low. When such a reaction system using a biological sample derived from a normal subject or a biological sample derived from a patient without cognitive impairment (e.g., a patient with Parkinson's disease) is used as a control, a subject can be assessed as suffering from or being at risk of suffering from a neurological disease associated with cognitive impairment if the EphA4 extracellular domain derived from the subject is lower than the control. For this reason, the EphA4 extracellular domain can be used as a biomarker for neurological diseases associated with cognitive impairment.

25 **[0027]** Examples of "EphA4" intended in the present invention include human EphA4 (NM_004438.3, NP_004429.1, BAG35298.1 (SEQ ID NO: 1), BC026327 (SEQ ID NO: 2), and so on.

30 **[0028]** In a preferred embodiment of the present invention, EphA4 is human EphA4, for example, a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 1 or 2.

35 **[0029]** In the present invention, the EphA4 extracellular domain which serves as a biomarker for neurological diseases associated with cognitive impairment is preferably in its full-length form, but a partial sequence thereof or a mutated sequence thereof may also be possible. A mutant of EphA4 may be a polypeptide substantially functionally equivalent to EphA4, which comprises an amino acid sequence with deletion, substitution, insertion and/or addition of one or more (preferably one or several) amino acids in the full-length or partial sequence of EphA4 or with any combination of these modifications. Such a "polypeptide substantially functionally equivalent to EphA4" is intended to mean a polypeptide having the activity of EphA4, such as MMP- or γ -secretase-dependent cleavage activity, i.e., a peptide serving as a substrate for matrix metalloproteinase or γ -secretase.

40 **[0030]** As used herein, the term "substitution" is preferably intended to mean conservative substitution, in which one or more (preferably one or several) amino acid residues are replaced with other chemically similar amino acid residues such that the activity of the resulting polypeptide is not substantially altered. Examples include cases where one hydrophobic residue is replaced with another hydrophobic residue and where one polar residue is replaced with another polar residue having the same charge. For each amino acid, its functionally similar amino acids allowing such substitution are known in the art. More specifically, examples of non-polar (hydrophobic) amino acids include alanine, valine, isoleucine, leucine, proline, tryptophan, phenylalanine, methionine and so on. Examples of polar (neutral) amino acids include glycine, serine, threonine, tyrosine, glutamine, asparagine, cysteine and so on. Examples of positively charged (basic) amino acids include arginine, histidine, lysine and so on. Likewise, examples of negatively charged (acidic) amino acids include aspartic acid, glutamic acid and so on.

45 **[0031]** The number of amino acids which may be deleted, substituted, inserted and/or added as described above is,

e.g., 1 to 30, preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to 5, and particularly preferably 1 or 2.

[0032] Mutated amino acid sequences of EphA4 include amino acid sequences each sharing a homology of preferably 80% or more, more preferably 85% or more, even more preferably 90% or more, still even more preferably 95% or more, particularly preferably 98% or more, and most preferably 99% or more with the amino acid sequence of the wild-type polypeptide. Polypeptides comprising amino acid sequences each having the above homology fall within mutated polypeptides to be used in the present invention, as long as they have substantially the same activity as EphA4, e.g., the activity to receive MMP-mediated or γ -secretase-mediated cleavage (i.e., the activity to serve as a substrate for MMP or γ -secretase). Moreover, the above mutated polypeptides can be used as targets to be detected, as long as they have another activity, e.g., the activity to cause a morphological change in postsynapses, particularly to cause an Ephrin A-dependent morphological change, in addition to the above activity to serve as a substrate for MMP or γ -secretase. The activity to serve as a substrate for MMP or γ -secretase can be detected by ELISA or Western blotting, etc.

[0033] The above identity may be a numerical value calculated using any homology search program known to those skilled in the art, for example, may be calculated using default (initial setting) parameters in the homology algorithm BLAST (basic local alignment search tool) program of the National Center for Biotechnology Information (NCBI), available at <http://www.ncbi.nlm.nih.gov/BLAST/>.

[0034] In the present invention, the EphA4 extracellular domain is preferably endogenous. In the case of endogenous EphA4 extracellular domain, any composition is possible as long as it contains the EphA4 extracellular domain derived from a part of a subject. Such a part of a subject may be, for example, a tissue, a cell, a cell membrane fraction or a purified membrane, each of which is derived from the above subject. Examples of such a cell include neuronal cells (e.g., cells in the central nervous system brain-derived neurons, cerebral cortex-derived neurons, cerebral cortex-derived primary cultured neurons, hippocampus-derived primary cultured neurons), glia cells and so on.

[0035] Moreover, in these cells, the EphA4 extracellular domain may remain in the state of being contained in a part of the subject or may be an EphA4 extracellular domain fraction of a cell lysate prepared from the subject. Such a cell lysate may be prepared from EphA4-containing cells, e.g., by lysis with a hypotonic solution or a surfactant or by ultrasonic or physical homogenization, optionally followed by treatment with a purification means such as a column.

[0036] For analysis of EphA4 cleavage, an antibody which binds to the full-length EphA4 may be used, but it is necessary to use an antibody which recognizes the EphA4 extracellular domain, because the amount of the EphA4 extracellular domain (N-terminal fragment) should be measured.

[0037] The EphA4 extracellular domain may be quantified by measuring signals generated when the labeled antibody binds to the EphA4 extracellular domain.

[0038] Examples of the above label include biotin labels, enzyme labels, radioactive labels, fluorescent labels, chemiluminescent labels and so on. Moreover, modifications may also be made to integrate any detectable moiety in addition to the label. In the present invention, the antibody for use in analysis of EphA4 cleavage may be provided with one or two or more of these labels or modifications.

[0039] The antibody for use in analysis of EphA4 cleavage may be an antibody against EphA4 and is not limited in any way as long as it is an antibody which recognizes EphA4, as exemplified by an antibody which recognizes the EphA4 extracellular domain.

[0040] Those skilled in the art would be able to prepare such an antibody by immunization with an immunogen (antigen) in accordance with existing standard procedures for monoclonal antibody preparation. For example, the antigen is immunized into a non-human mammal, optionally together with Freund's adjuvant. Polyclonal antibodies can be obtained from the serum taken from the immunised animal. On the other hand, monoclonal antibodies are prepared as follows: antibody-producing cells obtained from the immunized animal and myeloma cells having no ability to produce autoantibodies are used to prepare fused cells (hybridomas), and these hybridomas are cloned and screened to select clones which produce monoclonal antibodies having specific affinity to the antigen used for immunization of the mammal. Production of monoclonal antibodies from hybridomas may be accomplished by culturing the hybridomas *in vitro* or *in vivo* (e.g., in the peritoneal fluid of non-human mammals, preferably mice or rats, more preferably mice) and then isolating monoclonal antibodies from the resulting culture supernatant or the peritoneal fluid of the mammals. For isolation and purification of monoclonal antibodies, the above culture supernatant or peritoneal fluid may be subjected to saturated ammonium sulfate, euglobulin precipitation, caproic acid method, caprylic acid method, ion exchange chromatography (e.g., DEAE or DE52), affinity column chromatography on an anti-immunoglobulin column or a Protein A column, etc. These monoclonal antibodies also encompass those consisting of heavy chains and/or light chains having amino acid sequences with deletion, substitution or addition of one or several amino acids in the amino acid sequences of the heavy chains and/or light chains constituting the original antibodies.

[0041] In the present invention, it is possible to use anti-human EphA4 monoclonal antibody No. 8 (i.e., a monoclonal antibody which binds to the EphA4 extracellular domain) and so on, as shown in the Example section below.

[0042] In the present invention, the EphA4 extracellular domain can be used as a clinical biomarker for neurological diseases associated with cognitive impairment. By measuring the amount of the EphA4 extracellular domain in a biological sample, a neurological disease associated with cognitive impairment can be detected on the basis of the measured results.

<Biological sample>

5 [0043] The biological sample is not limited in any way and examples include liquid components derived from the living body (also collectively referred to as body fluid) such as blood and blood components (e.g., serum, plasma, blood cells), urine, spinal fluid, saliva, lacrimal fluid, sweat and so on, as well as solid components derived from the living body such as hair, tissue pieces excised by biopsy, etc. Preferred is blood or a blood component, and particularly preferred is serum or plasma. It should be noted that a sample taken from the living body may be used directly or further subjected to some kind of treatment for use as a biological sample in the present invention.

10 <Measurement of the amount of the EphA4 extracellular domain>

15 [0044] The amount of the EphA4 extracellular domain may be measured by any technique as long as it has sufficient detection sensitivity and measurement accuracy, and known analysis techniques may be used for this purpose. Examples of analysis techniques include immunological assays such as ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay), sandwich ELISA, immuno-complex transfer (ICT), antibody PCR (immuno-PCR), EIA (enzyme immuno assay), CLIA (chemiluminescent immuno assay), ECLIA (electrochemiluminescence immuno assay), FIA (fluorescent immuno assay) and so on, as well as surface plasmon resonance such as biacore. Moreover, known analysis techniques and immunological assays may be used in combination for measurement. In this case, preferred is a combination of ICT and another immunological assay, as exemplified by ICT-ELISA, ICT-CLIA, ICT-immuno-PCR, ICT-EIA, ICT-RIA, ICT-ECLIA, ICT-FIA, etc.

20 [0045] Preferred neurological diseases associated with cognitive impairment to be detected in the present invention may be, for example, diseases with reduced neuronal activity in glutamatergic neurons. The phrase "with reduced neuronal activity in glutamatergic neurons" is intended to mean a reduced amount of glutamic acid released from the nerve endings of glutamatergic neurons or reduced functions of neuronal glutamate receptors projected from glutamatergic neurons. Confirmation of whether or not the neuronal activity in glutamatergic neurons is reduced may be accomplished by detecting changes in the amount of EphA4 cleaved in a neuronal activity-dependent manner. Particularly preferred neurological diseases associated with cognitive impairment include, for example, Alzheimer's disease, mild cognitive impairment (MIC) or frontotemporal dementia (Pick's disease), etc.

25 [0046] The mean value of EphA4 extracellular domain levels is about 0.1 ng/mL plasma in normal subjects. In contrast, among patients with neurological diseases associated with cognitive impairment, Alzheimer's disease (AD) patients often are at about half level or less of normal subjects' concentration ($P < 0.01$), which is almost impossible to detect (below the detection limit). Mild cognitive impairment (MCI) patients also often are at about half level or less of the mean value in normal subjects' concentration (0.1 ng/mL) ($P < 0.05$), which is below the detection limit. Thus, in the present invention, the above mean value can be used as a standard for detection or diagnosis of a neurological disease associated with cognitive impairment,

30 [0047] In the method of the present invention, biological tissue samples derived from a plurality of subjects may be used in some cases for measurement of EphA4 extracellular domain levels. Thus, in the predetermined number of patients with neurological diseases associated with cognitive impairment (primary population), the amount of the EphA4 extracellular domain may be measured and processed by statistical analysis or the like for comparison with the control. Moreover, the resulting measured values may be used as basic data, and a comparison may be made between these basic data and the amount of the EphA4 extracellular domain in a biological sample or samples taken from a subject or subjects to be detected.

35 [0048] Further, if the above measured data of the subjects fall within the predetermined range of values, they may be incorporated into the values of the above population and subjected again to data processing (e.g., data averaging) of EphA4 extracellular domain levels to increase the number of cases of target patients (population). The increased number of cases can improve the accuracy of detection or diagnosis of a neurological disease associated with cognitive impairment.

40 <Kit>

50 [0049] In the present invention, the EphA4 extracellular domain serves as a marker for neurological diseases associated with cognitive impairment. Thus, an antibody which binds to the EphA4 extracellular domain can be used as an assay kit designed for *in vitro* experiments or for patients with neurological diseases associated with cognitive impairment. In this case, the present invention can be configured in the form of a kit comprising an antibody which binds to the EphA4 extracellular domain or at least one member selected from a buffer, a cell culture medium, an antibody which binds to the EphA4 extracellular domain, a fluorescent dye and so on. Such a kit may also comprise an instruction manual which describes, e.g., test procedures for binding assay between anti-EphA4 extracellular domain antibody and EphA4 extracellular domain.

[0050] The kit of the present invention may comprise tools for use in ELISA, immunoblotting and/or Western blotting techniques (e.g., reaction container, blotting membrane), reagents (e.g., buffer, culture medium), an instruction manual, etc.

5 EXAMPLES

[0051] The present invention will be further described in more detail by way of the following examples, which are not intended to limit the scope of the present invention.

10 [Example 1]

<Measurement of EphA4 extracellular domain concentration>

~ELISA-based measurement~

15 [0052] Anti-human EphA4 extracellular domain monoclonal antibody No. 8 (Eisai Co., Ltd., Japan) was purified and adjusted with 50 mM Tris/HCl (pH 7.5) to a concentration of 5 μ g/ml, and then injected at 100 μ l/well in a Maxisorp cup (NUNC). The cup was placed in a humid box and coated overnight at 4°C. After the antibody solution was removed by aspiration, a blocking solution (5% skimmed milk (Morinaga Milk Industry Co., Ltd., Japan), 50 mM Tris/HCl (pH 7.5), 20 150 mM NaCl, 0.1% sodium azide) was injected at 200 μ l/well, followed by blocking at room temperature for 2 hours or at 4°C for one day or more (hereinafter referred to as "No. 8 cup"). Anti-human EphA4 extracellular domain monoclonal antibody No. 9 (Eisai Co., Ltd., Japan) was labeled with peroxidase using a Peroxidase Labeling Kit-NH₂ (DOJINDO MOLECULAR TECHNOLOGIES, Inc.) in accordance with the instruction manual attached to the kit (hereinafter referred to as "peroxidase-labeled No. 9 antibody"),

25 [0053] The No. 8 cup was washed three times with a washing solution (50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.01% Tween 20), and a sample which had been diluted 5-fold with an analyte diluent (5% skimmed milk (Morinaga Milk Industry Co., Ltd., Japan), 50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.2% EDTA·3Na, 4% polyethylene glycol 6000, 0.1% sodium azide) was injected at 100 μ l/well and reacted at room temperature for 2 hours. After washing three times with the washing solution, the peroxidase-labeled No. 9 antibody which had been diluted 1500-fold with a labeled antibody diluent 30 (5% skimmed milk (Morinaga Milk Industry Co., Ltd., Japan), 50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.2% EDTA·3Na, 4% polyethylene glycol 6000, 0.2% ProClin 150 (SUPELCO, 49376-U)) was injected at 100 μ l/well and reacted at room temperature for 1 hour. After washing three times with the washing solution, a 3,3',5,5'-Tetramethylbenzidine (TMB) Liquid Substrate System for ELISA (SIGMA) was injected at 100 μ l/well and reacted at room temperature for 30 minutes. 0.5 M H₂SO₄ was injected at 100 μ l/well to stop the reaction, and OD (450 to 650 nm) was then measured for each well. 35 The purified recombinant human EphA4 (Eisai Co., Ltd., Japan) was used as a standard to calculate the EphA4 concentration.

[0054] Figure 2 shows the results measured for the plasma analytes obtained from 10 cases of Alzheimer's disease patients (AD), 10 cases of mild cognitive impairment patients (MCI), 10 cases of schizophrenia patients (Schizophrenia), 4 cases of Parkinson's disease patients (PD) and 36 cases of normal subjects (Normal).

40 [0055] The EphA4 concentration was below the detection limit in 8 of the 10 AD cases, 7 of the 10 MCI cases, 4 of the 10 schizophrenia cases, 0 of the 4 PD cases, and 3 of the 36 normal cases. The cases below the detection limit were statistically analyzed by using a provisional value below the detection limit, indicating that AD showed a significantly lower value than Normal at a significance level of less than 1% and also showed a significantly lower value than PD at a significance level of less than 5% in the Mann-Whitney U-test. Likewise, MCI also showed a significantly lower value 45 than Normal at a significance level of less than 5%.

INDUSTRIAL APPLICABILITY

50 [0056] The present invention enables the detection of neurological diseases associated with cognitive impairment by using the EphA4 extracellular domain as a biological indicator (biomarker).

55

EP 2 703 814 A1

SEQUENCE LISTING

<110> Eisai R&D Management Co., Ltd.

5 <120> A method of detecting a neuronal system disease associated with
cognitive impairment by measurement of EphA4-extracellular domain

<130> PCT12-0014

10 <150> JP 2011-097377
<151> 2011-04-25

<160> 2

<170> PatentIn version 3.4

15 <210> 1
<211> 986
<212> PRT
<213> Homo sapiens

20 <400> 1

Met Ala Gly Ile Phe Tyr Phe Ala Leu Phe Ser Cys Leu Phe Gly Ile
1 5 10 15

25 Cys Asp Ala Val Thr Gly Ser Arg Val Tyr Pro Ala Asn Glu Val Thr
20 25 30

30 Leu Leu Asp Ser Arg Ser Val Gln Gly Glu Leu Gly Trp Ile Ala Ser
35 40 45

35 Pro Leu Glu Gly Gly Trp Glu Glu Val Ser Ile Met Asp Glu Lys Asn
50 55 60

40 Thr Pro Ile Arg Thr Tyr Gln Val Cys Asn Val Met Glu Pro Ser Gln
65 70 75 80

45 Asn Asn Trp Leu Arg Thr Asp Trp Ile Thr Arg Glu Gly Ala Gln Arg
85 90 95

50 Val Tyr Ile Glu Ile Lys Phe Thr Leu Arg Asp Cys Asn Ser Leu Pro
100 105 110

Gly Val Met Gly Thr Cys Lys Glu Thr Phe Asn Leu Tyr Tyr Tyr Glu
115 120 125

55 Ser Asp Asn Asp Lys Glu Arg Phe Ile Arg Glu Asn Gln Phe Val Lys
130 135 140

Ile Asp Thr Ile Ala Ala Asp Glu Ser Phe Thr Gln Val Asp Ile Gly
145 150 155 160

EP 2 703 814 A1

Asp Arg Ile Met Lys Leu Asn Thr Glu Ile Arg Asp Val Gly Pro Leu
 165 170 175
 5 Ser Lys Lys Gly Phe Tyr Leu Ala Phe Gln Asp Val Gly Ala Cys Ile
 180 185 190
 10 Ala Leu Val Ser Val Arg Val Phe Tyr Lys Lys Cys Pro Leu Thr Val
 195 200 205
 Arg Asn Leu Ala Gln Phe Pro Asp Thr Ile Thr Gly Ala Asp Thr Ser
 210 215 220
 15 Ser Leu Val Glu Val Arg Gly Ser Cys Val Asn Asn Ser Glu Glu Lys
 225 230 235 240
 20 Asp Val Pro Lys Met Tyr Cys Gly Ala Asp Gly Glu Trp Leu Val Pro
 245 250 255
 25 Ile Gly Asn Cys Leu Cys Asn Ala Gly His Glu Glu Arg Ser Gly Glu
 260 265 270
 Cys Gln Ala Cys Lys Ile Gly Tyr Tyr Lys Ala Leu Ser Thr Asp Ala
 275 280 285
 30 Thr Cys Ala Lys Cys Pro Pro His Ser Tyr Ser Val Trp Glu Gly Ala
 290 295 300
 35 Thr Ser Cys Thr Cys Asp Arg Gly Phe Phe Arg Ala Asp Asn Asp Ala
 305 310 315 320
 Ala Ser Met Pro Cys Thr Arg Pro Pro Ser Ala Pro Leu Asn Leu Ile
 325 330 335
 40 Ser Asn Val Asn Glu Thr Ser Val Asn Leu Glu Trp Ser Ser Pro Gln
 340 345 350
 45 Asn Thr Gly Gly Arg Gln Asp Ile Ser Tyr Asn Val Val Cys Lys Lys
 355 360 365
 50 Cys Gly Ala Gly Asp Pro Ser Lys Cys Arg Pro Cys Gly Ser Gly Val
 370 375 380
 His Tyr Thr Pro Gln Gln Asn Gly Leu Lys Thr Thr Lys Val Ser Ile
 385 390 395 400
 55 Thr Asp Leu Leu Ala His Thr Asn Tyr Thr Phe Glu Ile Trp Ala Val
 405 410 415

EP 2 703 814 A1

Asn Gly Val Ser Lys Tyr Asn Pro Asn Pro Asp Gln Ser Val Ser Val
 420 425 430
 5 Thr Val Thr Thr Asn Gln Ala Ala Pro Ser Ser Ile Ala Leu Val Gln
 435 440 445
 10 Ala Lys Glu Val Thr Arg Tyr Ser Val Ala Leu Ala Trp Leu Glu Pro
 450 455 460
 15 Asp Arg Pro Asn Gly Val Ile Leu Glu Tyr Glu Val Lys Tyr Tyr Glu
 465 470 475 480
 20 Lys Asp Gln Asn Glu Arg Ser Tyr Arg Ile Val Arg Thr Ala Ala Arg
 485 490 495
 25 Asn Thr Asp Ile Lys Gly Leu Asn Pro Leu Thr Ser Tyr Val Phe His
 500 505 510
 Val Arg Ala Arg Thr Ala Ala Gly Tyr Gly Asp Phe Ser Glu Pro Leu
 515 520 525
 30 Glu Val Thr Thr Asn Thr Val Pro Ser Arg Ile Ile Gly Asp Gly Ala
 530 535 540
 35 Asn Ser Thr Val Leu Leu Val Ser Val Ser Gly Ser Val Val Leu Val
 545 550 555 560
 Val Ile Leu Ile Ala Ala Phe Val Ile Ser Arg Arg Arg Ser Lys Tyr
 565 570 575
 40 Ser Lys Ala Lys Gln Glu Ala Asp Glu Glu Lys His Leu Asn Gln Gly
 580 585 590
 Val Arg Thr Tyr Val Asp Pro Phe Thr Tyr Glu Asp Pro Asn Gln Ala
 595 600 605
 45 Val Arg Glu Phe Ala Lys Glu Ile Asp Ala Ser Cys Ile Lys Ile Glu
 610 615 620
 50 Lys Val Ile Gly Val Gly Glu Phe Gly Glu Val Cys Ser Gly Arg Leu
 625 630 635 640
 Lys Val Pro Gly Lys Arg Glu Ile Cys Val Ala Ile Lys Thr Leu Lys
 645 650 655
 55 Ala Gly Tyr Thr Asp Lys Gln Arg Arg Asp Phe Leu Ser Glu Ala Ser
 660 665 670

EP 2 703 814 A1

Ile Met Gly Gln Phe Asp His Pro Asn Ile Ile His Leu Glu Gly Val
675 680 685

5 Val Thr Lys Cys Lys Pro Val Met Ile Ile Thr Glu Tyr Met Glu Asn
690 695 700

10 Gly Ser Leu Asp Ala Phe Leu Arg Lys Asn Asp Gly Arg Phe Thr Val
705 710 715 720

Ile Gln Leu Val Gly Met Leu Arg Gly Ile Gly Ser Gly Met Lys Tyr
725 730 735

15 Leu Ser Asp Met Ser Tyr Val His Arg Asp Leu Ala Ala Arg Asn Ile
740 745 750

20 Leu Val Asn Ser Asn Leu Val Cys Lys Val Ser Asp Phe Gly Met Ser
755 760 765

25 Arg Val Leu Glu Asp Asp Pro Glu Ala Ala Tyr Thr Thr Arg Gly Gly
770 775 780

Lys Ile Pro Ile Arg Trp Thr Ala Pro Glu Ala Ile Ala Tyr Arg Lys
785 790 795 800

30 Phe Thr Ser Ala Ser Asp Val Trp Ser Tyr Gly Ile Val Met Trp Glu
805 810 815

35 Val Met Ser Tyr Gly Glu Arg Pro Tyr Trp Asp Met Ser Asn Gln Asp
820 825 830

40 Val Ile Lys Ala Ile Glu Glu Gly Tyr Arg Leu Pro Pro Pro Met Asp
835 840 845

Cys Pro Ile Ala Leu His Gln Leu Met Leu Asp Cys Trp Gln Lys Glu
850 855 860

45 Arg Ser Asp Arg Pro Lys Phe Gly Gln Ile Val Asn Met Leu Asp Lys
865 870 875 880

50 Leu Ile Arg Asn Pro Asn Ser Leu Lys Arg Thr Gly Thr Glu Ser Ser
885 890 895

Arg Pro Asn Thr Ala Leu Leu Asp Pro Ser Ser Pro Glu Phe Ser Ala
900 905 910

55 Val Val Ser Val Gly Asp Trp Leu Gln Ala Ile Lys Met Asp Arg Tyr

EP 2 703 814 A1

	915		920		925												
5	Lys	Asp	Asn	Phe	Thr	Ala	Ala	Gly	Tyr	Thr	Thr	Leu	Glu	Ala	Val	Val	
	930						935					940					
10	His	Val	Asn	Gln	Glu	Asp	Leu	Ala	Arg	Ile	Gly	Ile	Thr	Ala	Ile	Thr	
	945					950					955					960	
15	His	Gln	Asn	Lys	Ile	Leu	Ser	Ser	Val	Gln	Ala	Met	Arg	Thr	Gln	Met	
					965					970					975		
20	Gln	Gln	Met	His	Gly	Arg	Met	Val	Pro	Val							
				980					985								
	<210>	2															
	<211>	949															
	<212>	PRT															
	<213>	Homo sapiens															
	<400>	2															
25	Met	Ala	Gly	Ile	Phe	Tyr	Phe	Ala	Leu	Phe	Ser	Cys	Leu	Phe	Gly	Ile	
	1			5						10					15		
30	Cys	Asp	Ala	Val	Thr	Gly	Ser	Arg	Val	Tyr	Pro	Ala	Asn	Glu	Val	Thr	
				20					25					30			
35	Leu	Leu	Asp	Ser	Arg	Ser	Val	Gln	Gly	Glu	Leu	Gly	Trp	Ile	Ala	Ser	
			35					40					45				
40	Pro	Leu	Glu	Gly	Gly	Trp	Glu	Glu	Val	Ser	Ile	Met	Asp	Glu	Lys	Asn	
		50					55					60					
45	Thr	Pro	Ile	Arg	Thr	Tyr	Gln	Val	Cys	Asn	Val	Met	Glu	Pro	Ser	Gln	
	65					70					75					80	
50	Asn	Asn	Trp	Leu	Arg	Thr	Asp	Trp	Ile	Thr	Arg	Glu	Gly	Ala	Gln	Arg	
				85						90					95		
55	Val	Tyr	Ile	Glu	Ile	Lys	Phe	Thr	Leu	Arg	Asp	Cys	Asn	Ser	Leu	Pro	
				100					105						110		
60	Gly	Val	Met	Gly	Thr	Cys	Lys	Glu	Thr	Phe	Asn	Leu	Tyr	Tyr	Tyr	Glu	
			115					120					125				
65	Ser	Asp	Asn	Asp	Lys	Glu	Arg	Phe	Ile	Arg	Glu	Asn	Gln	Phe	Val	Lys	
		130					135					140					
70	Ile	Asp	Thr	Ile	Ala	Ala	Asp	Glu	Ser	Phe	Thr	Gln	Val	Asp	Ile	Gly	

EP 2 703 814 A1

	145					150						155				160
5	Asp	Arg	Ile	Met	Lys	Leu	Asn	Thr	Glu	Ile	Arg	Asp	Val	Gly	Pro	Leu
					165					170					175	
10	Ser	Lys	Lys	Gly	Phe	Tyr	Leu	Ala	Phe	Gln	Asp	Val	Gly	Ala	Cys	Ile
			180						185					190		
15	Ala	Leu	Val	Ser	Val	Arg	Val	Phe	Tyr	Lys	Lys	Cys	Pro	Leu	Thr	Val
			195					200					205			
20	Arg	Asn	Leu	Ala	Gln	Phe	Pro	Asp	Thr	Ile	Thr	Gly	Ala	Asp	Thr	Ser
		210					215					220				
25	Ser	Leu	Val	Glu	Val	Arg	Gly	Ser	Cys	Val	Asn	Asn	Ser	Glu	Glu	Lys
	225					230					235					240
30	Asp	Val	Pro	Lys	Met	Tyr	Cys	Gly	Ala	Asp	Gly	Glu	Trp	Leu	Val	Pro
					245					250					255	
35	Ile	Gly	Asn	Cys	Leu	Cys	Asn	Ala	Gly	His	Glu	Glu	Arg	Ser	Gly	Glu
			260						265					270		
40	Cys	Gln	Ala	Cys	Lys	Ile	Gly	Tyr	Tyr	Lys	Ala	Leu	Ser	Thr	Asp	Ala
			275					280					285			
45	Thr	Cys	Ala	Lys	Cys	Pro	Pro	His	Ser	Tyr	Ser	Val	Trp	Glu	Gly	Ala
	290					295						300				
50	Thr	Ser	Cys	Thr	Cys	Asp	Arg	Gly	Phe	Phe	Arg	Ala	Asp	Asn	Asp	Ala
	305					310					315					320
55	Ala	Ser	Met	Pro	Cys	Thr	Arg	Pro	Pro	Ser	Ala	Pro	Leu	Asn	Leu	Ile
					325					330					335	
60	Ser	Asn	Val	Asn	Glu	Thr	Ser	Val	Asn	Leu	Glu	Trp	Ser	Ser	Pro	Gln
				340					345					350		
65	Asn	Thr	Gly	Gly	Arg	Gln	Asp	Ile	Ser	Tyr	Asn	Val	Val	Cys	Lys	Lys
			355					360					365			
70	Cys	Gly	Ala	Gly	Asp	Pro	Ser	Lys	Cys	Arg	Pro	Cys	Gly	Ser	Gly	Val
	370					375						380				
75	His	Tyr	Thr	Pro	Gln	Gln	Asn	Gly	Leu	Lys	Thr	Thr	Lys	Val	Ser	Ile
	385					390					395					400

EP 2 703 814 A1

Thr Asp Leu Leu Ala His Thr Asn Tyr Thr Phe Glu Ile Trp Ala Val
 405 410 415
 5 Asn Gly Val Ser Lys Tyr Asn Pro Asn Pro Asp Gln Ser Val Ser Val
 420 425 430
 10 Thr Val Thr Thr Asn Gln Ala Ala Pro Ser Ser Ile Ala Leu Val Gln
 435 440 445
 Ala Lys Glu Val Thr Arg Tyr Ser Val Ala Leu Ala Trp Leu Glu Pro
 450 455 460
 15 Asp Arg Pro Asn Gly Val Ile Leu Glu Tyr Glu Val Lys Tyr Tyr Glu
 465 470 475 480
 20 Lys Asp Gln Asn Glu Arg Ser Tyr Arg Ile Val Arg Thr Ala Ala Arg
 485 490 495
 Asn Thr Asp Ile Lys Gly Leu Asn Pro Leu Thr Ser Tyr Val Phe His
 500 505 510
 25 Val Arg Ala Arg Thr Ala Ala Gly Tyr Gly Asp Phe Ser Glu Pro Leu
 515 520 525
 30 Glu Val Thr Thr Asn Thr Val Pro Ser Arg Ile Ile Gly Asp Gly Ala
 530 535 540
 Asn Ser Thr Val Leu Leu Val Ser Val Ser Gly Ser Val Val Leu Val
 545 550 555 560
 35 Val Ile Leu Ile Ala Ala Phe Val Ile Ser Arg Arg Arg Ser Lys Tyr
 565 570 575
 40 Ser Lys Ala Lys Gln Glu Ala Asp Glu Glu Lys His Leu Asn Gln Gly
 580 585 590
 45 Val Arg Thr Tyr Val Asp Pro Phe Thr Tyr Glu Asp Pro Asn Gln Ala
 595 600 605
 Val Arg Glu Phe Ala Lys Glu Ile Asp Ala Ser Cys Ile Lys Ile Glu
 610 615 620
 50 Lys Val Ile Gly Val Gly Glu Phe Gly Glu Val Cys Ser Gly Arg Leu
 625 630 635 640
 55 Lys Val Pro Gly Lys Arg Glu Ile Cys Val Ala Ile Lys Thr Leu Lys
 645 650 655

EP 2 703 814 A1

Ala Gly Tyr Thr Asp Lys Gln Arg Arg Asp Phe Leu Ser Glu Ala Ser
660 665 670

5 Ile Met Gly Gln Phe Asp His Pro Asn Ile Ile His Leu Glu Gly Val
675 680 685

Val Thr Lys Cys Lys Pro Val Met Ile Ile Thr Glu Tyr Met Glu Asn
10 690 695 700

Gly Ser Leu Asp Ala Phe Leu Arg Lys Asn Asp Gly Arg Phe Thr Val
15 705 710 715 720

Ile Gln Leu Val Gly Met Leu Arg Gly Ile Gly Ser Gly Met Lys Tyr
725 730 735

20 Leu Ser Asp Met Ser Tyr Val His Arg Asp Leu Ala Ala Arg Asn Ile
740 745 750

Leu Val Asn Ser Asn Leu Val Cys Lys Val Ser Asp Phe Gly Met Ser
25 755 760 765

Arg Val Leu Glu Asp Asp Pro Glu Ala Ala Tyr Thr Thr Arg Gly Gly
770 775 780

30 Lys Ile Pro Ile Arg Trp Thr Ala Pro Glu Ala Ile Ala Tyr Arg Lys
785 790 795 800

Phe Thr Ser Ala Ser Asp Val Trp Ser Tyr Gly Ile Val Met Trp Glu
35 805 810 815

Val Met Ser Tyr Gly Glu Arg Pro Tyr Trp Asp Met Ser Asn Gln Asp
40 820 825 830

Val Ile Lys Ala Ile Glu Glu Gly Tyr Arg Leu Pro Pro Pro Met Asp
45 835 840 845

Cys Pro Ile Ala Leu His Gln Leu Met Leu Asp Cys Trp Gln Lys Glu
850 855 860

Arg Ser Asp Arg Pro Lys Phe Gly Gln Ile Val Asn Met Leu Asp Lys
50 865 870 875 880

Leu Ile Arg Asn Pro Asn Ser Leu Lys Arg Thr Gly Thr Glu Ser Ser
885 890 895

55 Arg Pro Asn Thr Ala Leu Leu Asp Pro Ser Ser Pro Glu Phe Ser Ala
900 905 910

EP 2 703 814 A1

Val Val Ser Val Gly Asp Trp Leu Gln Val Ile Lys Met Asp Arg Tyr
915 920 925

5 Lys Asp Asn Phe Thr Ala Ala Gly Tyr Thr Thr Leu Glu Ala Val Val
930 935 940

10 His Val Asn Gln Glu
945

Claims

- 15 1. A biomarker for a neurological disease associated with cognitive impairment, which comprises the extracellular domain of EphA4.
2. The marker according to claim 1, wherein said EphA4 is a protein shown in (a) or (b) below:
- 20 (a) a protein which consists of the amino acid sequence shown in SEQ ID NO: 1 or 2; or
(b) a protein which consists of an amino acid sequence with deletion, substitution or addition of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 1 or 2 and which serves as a substrate for matrix metalloproteinase or γ -secretase.
- 25 3. A method for detecting a neurological disease associated with cognitive impairment, which comprises the following steps:
- (a) contacting a biological sample taken from a subject with an antibody binding to the extracellular domain of EphA4 to thereby measure the amount of the EphA4 extracellular domain; and
- 30 (b) determining the subject as suffering from or being at risk of suffering from a neurological disease associated with cognitive impairment if the amount of the EphA4 extracellular domain derived from the subject is lower than a control.
- 35 4. A method for diagnosing a neurological disease associated with cognitive impairment, which comprises the following steps:
- (a) contacting a biological sample taken from a subject with an antibody binding to the extracellular domain of EphA4 to thereby measure the amount of the EphA4 extracellular domain; and
- 40 (b) diagnosing the subject as suffering from or being at risk of suffering from a neurological disease associated with cognitive impairment if the amount of the EphA4 extracellular domain derived from the subject is lower than a control.
5. The method according to claim 3 or 4, wherein the biological sample is a body fluid.
- 45 6. The method according to claim 5, wherein the body fluid is at least one selected from the group consisting of blood, serum, plasma, blood cells, urine, spinal fluid, saliva, lacrimal fluid and sweat.
7. The method according to any one of claims 3 to 6, wherein the amount of the EphA4 extracellular domain is measured by ELISA.
- 50 8. The method according to any one of claims 3 to 7, wherein the neurological disease associated with cognitive impairment is a disease with reduced neuronal activity in glutamatergic neurons.
9. The method according to any one of claims 3 to 8, wherein the neurological disease associated with cognitive impairment is Alzheimer's disease, mild cognitive impairment or frontotemporal dementia.
- 55 10. A kit for detecting or diagnosing a neurological disease associated with cognitive impairment, which comprises an antibody binding to the extracellular domain of EphA4.

Figure 1





Figure 2



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2012/061097

A. CLASSIFICATION OF SUBJECT MATTER G01N33/53(2006.01) i, C12N9/64(2006.01) n, C12N15/09(2006.01) n		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) G01N33/53, C12N9/64, C12N15/09		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2012 Kokai Jitsuyo Shinan Koho 1971-2012 Toroku Jitsuyo Shinan Koho 1994-2012		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) JSTPlus/JMEDPlus/JST7580 (JDreamII)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	INOUE Eiji et al., Synaptic activity prompts γ -secretase-mediated cleavage of EphA4 and dendritic spine formation, J. Cell Biol., 2009. 05.04, Vol.185, No.3, P.551-564	1,2,10
A	Eisaku ESUMI et al., "Expression of receptor type tyrosine kinase EphA4 in the spinal cord of autopsy and normal cases", Shinkei Hensei Shikkan ni Kansuru Kenkyuhan 2000 Nendo Kenkyu Hokokusho, 2001, pages 48 to 50	1,2,10
A	AOKI M. et al., EphA Receptors Direct the Differentiation of Mammalian Neural Precursor Cells through a Mitogen-activated Protein Kinase-dependent Pathway, J. Biol. Chem., 2004. 07.30, Vol.279, No.31, P.32643-32650	1,2,10
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 27 July, 2012 (27.07.12)		Date of mailing of the international search report 07 August, 2012 (07.08.12)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 2009)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2012/061097

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2008/150010 A1 (Eisai R & D Management Co., Ltd.), 11 December 2008 (11.12.2008), & US 2009/0142788 A1 & EP 2166110 A1 & AT 546543 T	1,2,10
A	WO 2009/069808 A1 (Eisai R & D Management Co., Ltd.), 04 June 2009 (04.06.2009), & US 2009/0275049 A1 & EP 2223999 A1	1,2,10
P,A	Eiji INOUE et al., "Alzheimer's Disease (AD) No ni Okeru EphA4/gamma-secretase Signal no Henka", Dement. Jpn., 15 November 2011 (15.10.2011), vol.25, no.3, page 339	1,2,10

Form PCT/ISA/210 (continuation of second sheet) (July 2009)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2012/061097

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 3-9
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 3 and 4, and claims 5 to 9 referring thereto pertain to diagnostic methods to be practiced on the human body and thus relate to a subject matter on which the International Searching Authority is not required to carry out a search under the provision of PCT Rule 39.1(iv).
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (July 2009)

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2008150010 A [0005]
- WO 2009069808 A [0005]
- JP 2011097377 A [0014]

Non-patent literature cited in the description

- **MURAI KK ; NGUYEN LN ; IRIE F ; YAMAGUCHI Y ; PASQUALE EB.** Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. *Nat Neurosci*, February 2003, vol. 6 (2), 153-60 [0006]
- **INOUE E ; DEGUCHI-TAWARADA M ; TOGAWA A ; MATSUI C ; ARITA K ; KATAHIRA-TAYAMA S ; SATO T ; YAMAUCHI E ; ODA Y ; TAKAI Y.** Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation. *J Cell Biol*, 04 May 2009, vol. 185 (3), 551-64 [0006]
- **MURAI KK et al.** *Nat Neurosci.*, February 2003, vol. 6 (2), 153-60 [0016]
- **AOTO, J et al.** *Brain Res.*, 2006, 11 [0016]

专利名称(译)	通过测量epha4细胞外结构域检测与认知功能障碍相关的神经疾病的方法		
公开(公告)号	EP2703814A1	公开(公告)日	2014-03-05
申请号	EP2012776929	申请日	2012-04-25
[标]申请(专利权)人(译)	卫材株式会社		
申请(专利权)人(译)	EISAI研发MANAGEMENT CO. , LTD.		
当前申请(专利权)人(译)	EISAI研发MANAGEMENT CO. , LTD.		
[标]发明人	OBARA TAKASHI INOUE EIJI		
发明人	OBARA, TAKASHI INOUE, EIJI		
IPC分类号	G01N33/53 C12N9/64 C12N15/09		
CPC分类号	G01N33/6896 C12N9/12 C12Y207/10001 G01N2800/2814 G01N2800/2821		
优先权	2011097377 2011-04-25 JP		
其他公开文献	EP2703814B1 EP2703814A4		
外部链接	Espacenet		

摘要(译)

一种用于检测与认知障碍相关的神经疾病的方法，其中EphA4的细胞外结构域是从取自受试者的生物样品中测量的。

SEQUENCE LISTING

```

<110> Eisai R&D Management Co., Ltd.
<120> A method of detecting a neuronal system disease associated with
cognitive impairment by measurement of EphA4-extracellular domain
<130> PCRI2-0014
<150> JP 2011-097377
<151> 2011-04-25
<160> 2
<170> PatentIn version 3.4
<210> 1
<211> 986
<212> PRT
<213> Homo sapiens
<400> 1
Met Ala Gly Ile Phe Tyr Phe Ala Leu Phe Ser Cys Leu Phe Gly Ile
1 5 10 15
Cys Asp Ala Val Thr Gly Ser Arg Val Tyr Pro Ala Asn Glu Val Thr
20 25
Leu Leu Asp Ser Arg Ser Val Gln Gly Glu Leu Gly Trp Ile Ala Ser
35 40
Pro Leu Glu Gly Gly Trp Glu Glu Val Ser Ile Met Asp Glu Lys Asn
50 55
Thr Pro Ile Arg Thr Tyr Gln Val Cys Asn Val Met Glu Pro Ser Gln
65 70 75 80
Asn Asn Trp Leu Arg Thr Asp Trp Ile Thr Arg Glu Gly Ala Gln Arg
85 90 95
Val Tyr Ile Glu Ile Lys Phe Thr Leu Arg Asp Cys Asn Ser Leu Pro
100 105 110
Gly Val Met Gly Thr Cys Lys Glu Thr Phe Asn Leu Tyr Tyr Glu
115 120 125
Ser Asp Asn Asp Lys Glu Arg Phe Ile Arg Glu Asn Gln Phe Val Lys
130 135 140
Ile Asp Thr Ile Ala Ala Asp Glu Ser Phe Thr Gln Val Asp Ile Gly
145 150 155 160

```